drugset / Trial / NCT05006469
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Observe the best dose, efficacy and adverse reactions of BAd in the treatment of relapsed and refractory multiple myeloma.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-05-31
- Completion
- 2024-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 70 mg/m2 | — |
| Subject | Bendamustine | Small molecule | 90 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 15 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Doxorubicin | Other / unclassified | 10 mg | — |